Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

BACKGROUND: CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of patients treated with checkpoint inhibitors. METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: DeLeon, Thomas T., Almquist, Daniel R., Kipp, Benjamin R., Langlais, Blake T., Mangold, Aaron, Winters, Jennifer L., Kosiorek, Heidi E., Joseph, Richard W., Dronca, Roxana S., Block, Matthew S., McWilliams, Robert R., Kottschade, Lisa A., Rumilla, Kandelaria M., Voss, Jesse S., Seetharam, Mahesh, Sekulic, Aleksandar, Markovic, Svetomir N., Bryce, Alan H.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083309/
https://ncbi.nlm.nih.gov/pubmed/32196516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0230306
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados